Journal of the Neurological Sciences 323 (2012) 271–272
Contents lists available at SciVerse ScienceDirect
Journal of the Neurological Sciences journal homepage: www.elsevier.com/locate/jns
Corrigendum
Corrigendum to “Hsp60 and AChR cross-reactivity in myasthenia gravis: An update.” [J. Neurol. Sci. 292 (2010) 117–118] Francesco Cappello a,⁎, Antonella Marino Gammazza a, Leila Zummo a, Everly Conway de Macario b, Alberto J.L. Macario b a b
Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Via del Vespro 129, 90127, Palermo, Italy University of Maryland, IMET, 701 East Pratt Street, 21202, Baltimore, MD, USA
The authors regret that when checking their proofs, it was overlooked that Table 1 contained serious errors. The sequence segments were not aligned as they should and the asterisks were misplaced. The authors would like to apologise for any inconvenience caused, and the corrected table appears on the next page.
DOI of original article: http://dx.doi.org/10.1016/j.jns.2010.02.021. ⁎ Corresponding author. E-mail address:
[email protected] (F. Cappello). 0022-510X/$ – see front matter © 2012 Elsevier B.V. All rights reserved. http://dx.doi.org/10.1016/j.jns.2012.07.052
272
F. Cappello et al. / Journal of the Neurological Sciences 323 (2012) 271–272
Table 1 Sequence segments of high similarity between human and chlamydial Hsp60 and various isoforms of human AChR.a
a = 53.8% H-Hsp60, 468 IKRTLKIPAMTIA AChRM2, 133 VKRTTKMAGMMIA *** * * ** b = 66.7% H-Hsp60, 197 GVITVKDGK AChRM2, 167 GVRTVEDGE ** ** ** c = 60.0% H-Hsp60, 449 PALDSLTPAN AChRM2, 332 PKSDSCTPTN * ** ** * d = 53.8% H-Hsp60, 489 LIVEKIMQSSSEV AChRA1, 279 VIVELIPSTSSAV *** * ** * e = 62.5% H-Hsp60, 327 EEGLTLNL AChRG, 69 EEALTTNV ** ** * f = 55.6% H-Hsp60, 451 LDSLTPANE AChRG, 217 LDPAAPAQE ** ** * g = 66.7% H-Hsp60, 534 GVASLLTTA AChRD, 409 GLARRLTTA * * **** h = 53.8% H-Hsp60, 489 LIVEKIMQSSSEV AChRB3, 245 LVIEEIIPSSSKV * * * *** * i = 55.6% H-Hsp60, 271 LVIIAEDVD AChRB3, 148 LILINENVD * * * ** j = 66.7% H-Hsp60, 396 KLSDGVAVL AChRB3, 345 QLSDGEKVL **** ** k = 53.8% H-Hsp60, 335 EDVQPHDLGKVGE AChRB3, 327 EESQPVVKGKVLE * ** *** * l = 60.0% CT-Hsp60, 507 SAASVAGLLL AChRM2, 107 SNASVMNLLI * *** *** m = 60.0% CT-Hsp60, 213 CVLEDALVLI AChRE, 251 CVLISGLVLL *** *** n = 55.6% CT-Hsp60, 273 VCAVKAPGF AChRE, 147 VCAVEVTYF **** * o = 62.5% CT-Hsp60, 512 AGLLLTTE AChRA1, 15 AGLVLGSE *** * *
p = 62.5% CT-Hsp60, 471 MSRSANEG AChRND, 361 MSRPAEDG *** * * q = 53.8% CT-Hsp60, 355 SSSDYDKEKLQER AChRND, 395 SRSDLMFEKQSER * ** ** ** r = 57.1% CT-Hsp60, 134 ISKPVQHHKEIAQV AChRB3, 377 ISQVVQDWKFVAQV ** ** * *** s = 55.6% CT-Hsp60, 336 GEKEALEAR AChRB3, 164 GEWEILNAK ** * * * t = 60.0% CP-Hsp60, 172 KERENDKTSM AChRM2, 280 KESSNDSTSV ** ** ** u = 55.6% CP-Hsp60, 421 DENSIAISL AChRM2, 304 DENTVSTSL *** ** v = 53.3% CP-Hsp60, 235 SEQNQHLIIFCEDID AChRA1, 353 SREKQDKKIFTEDID * * ** **** w = 55.6% CP-Hsp60, 2 SEQEKLSNY AChRA1, 182 SDQPDLSNF * * *** x = 87.5% CP-Hsp60, 366 LQSSVAIL AChRG, 254 LISSVAIL * ****** y = 55.6% CP-Hsp60, 43 FKERGFYAI AChRG, 200 FTENGEWAI * * * ** z = 55.6% CP-Hsp60, 16 LFSGIDKLF AChRD, 343 LSEGVKKLF * * *** aa = 62.5% CP-Hsp60, 304 LAPEMVTL AChRD, 103 LPPDMVWL * * ** * ab = 54.5% CP-Hsp60, 7 LSNYNADKKLF AChRB3, 150 LINENVDRKDF * * * * * * ac = 62.5% CP-Hsp60, 370 VAILPTDE AChRB3, 219 VFYLPSDE * ** **